House Democrat wants to know why a pharma insider is overseeing Trump’s drug pricing reform image

Vox, April 9, 2018
Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)


Read the Full Article

From the article:

House Democrats want to know why the Trump administration is letting a former pharmaceutical industry insider oversee its plans to fulfill President Donald Trump’s promises to bring down drug prices.

Rep. Keith Ellison (D-MN), one of the top progressives in the House and deputy chair of the Democratic National Committee, sent a letter Monday to HHS Secretary Alex Azar inquiring about the appointment of Daniel Best to oversee drug pricing reform. Best most recently worked at CVS CareMark before starting at HHS last week. He also worked at Pfizer for four years in the early 2000s.

Law professors Rachel Sachs and Nicholas Bagley examined those rationales for Health Affairs last week and found them wanting. They make a persuasive case that HHS is perfectly within its legal rights to approve the Massachusetts waiver and they also questioned why HHS would worry about setting a precedent for Medicaid drug formularies when it is eagerly encouraging states to establish Medicaid work requirements.

Read more here!

health care finance medicaremedicaid pharmaceuticals rachel sachs